Toshihiro Fukushima Selected Research

Dexamethasone (Maxidex)

9/2015	Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.
5/2012	[Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
10/2011	Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
6/2011	Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
9/2010	Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
8/2009	[Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshihiro Fukushima Research Topics

Disease

7	Multiple Myeloma 10/2013 - 08/2009
6	Fever (Fevers) 01/2023 - 06/2009
6	Immunoglobulin G4-Related Disease 12/2021 - 01/2012
6	Lymphoma (Lymphomas) 06/2011 - 06/2003
5	Thrombocytopenia (Thrombopenia) 04/2024 - 01/2013
5	Multi-centric Castleman's Disease 01/2023 - 01/2013
5	Neoplasms (Cancer) 10/2012 - 09/2005
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2012 - 02/2002
4	Edema (Dropsy) 01/2023 - 01/2013
3	Fibrosis (Cirrhosis) 01/2023 - 01/2013
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018 - 05/2003
2	B-Cell Lymphoma (Lymphoma, B Cell) 04/2024 - 09/2015
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2024 - 02/2014
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/2022 - 04/2012
2	Anemia 01/2019 - 12/2017
2	Primary Myelofibrosis (Myelosclerosis) 01/2019 - 12/2017
2	Splenomegaly 12/2017 - 02/2014
2	Body Weight (Weight, Body) 09/2017 - 01/2012
2	Plasmacytoma 10/2011 - 09/2010
2	Sepsis (Septicemia) 07/2010 - 08/2009
2	Rheumatoid Arthritis 10/2007 - 01/2006
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 02/2006 - 04/2004
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 09/2005 - 02/2005
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2004 - 06/2003
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 12/2021
1	Hypoalbuminemia 01/2019
1	Castleman Disease (Castleman's Disease) 12/2017
1	Vasculitis (Vasculitides) 01/2016
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 09/2015
1	Febrile Neutropenia 01/2015
1	Autoimmune Diseases (Autoimmune Disease) 02/2014
1	Residual Neoplasm 10/2013
1	Inflammation (Inflammations) 01/2013
1	Ascites 01/2013
1	Septic Shock (Toxic Shock Syndrome) 01/2013
1	Pleural Effusion (Pleural Effusions) 01/2013
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 10/2012
1	Philadelphia Chromosome 09/2012
1	Constipation 05/2012
1	Hepatitis 05/2012
1	Intestinal Pseudo-Obstruction (Intestinal Pseudoobstruction) 05/2012

Drug/Important Bio-Agent (IBA)

8	Immunoglobulin G (IgG)IBA 12/2021 - 01/2006
6	Dexamethasone (Maxidex)FDA LinkGeneric 09/2015 - 08/2009
5	Proteins (Proteins, Gene)FDA Link 12/2021 - 06/2003
5	Bortezomib (Velcade)FDA Link 12/2012 - 08/2009
4	GlucocorticoidsIBA 04/2024 - 01/2012
4	Reticulin (Reticular Fiber)IBA 01/2023 - 01/2013
4	C-Reactive ProteinIBA 07/2022 - 01/2013
4	Prednisolone (Predate)FDA LinkGeneric 12/2017 - 09/2010
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 05/2012
3	Rituximab (Mabthera)FDA Link 06/2016 - 05/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2015 - 02/2006
3	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2012 - 08/2009
2	Biomarkers (Surrogate Marker)IBA 12/2021 - 12/2017
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 06/2016 - 10/2005
2	AntigensIBA 01/2016 - 03/2007
2	SteroidsIBA 01/2015 - 01/2013
2	RNA (Ribonucleic Acid)IBA 01/2015 - 02/2006
2	CytokinesIBA 01/2015 - 05/2012
2	LeptinIBA 02/2014 - 01/2012
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2013 - 10/2005
2	Vincristine (Oncovin)FDA LinkGeneric 01/2013 - 10/2005
2	Etoposide (VP 16)FDA LinkGeneric 01/2013 - 02/2005
2	LipidsIBA 05/2012 - 12/2008
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2006 - 10/2005
1	COVID-19 VaccinesIBA 04/2024
1	belimumabIBA 04/2024
1	Ferritins (Ferritin)IBA 04/2024
1	CholesterolIBA 07/2022
1	AlbuminsIBA 07/2022
1	Blood Proteins (Serum Proteins)IBA 12/2021
1	SilverIBA 12/2021
1	Leucine (L-Leucine)FDA Link 12/2021
1	Immunoglobulins (Immunoglobulin)IBA 12/2021
1	ClusterinIBA 12/2021
1	Dasatinib (BMS 354825)FDA Link 01/2018
1	Immunosuppressive Agents (Immunosuppressants)IBA 06/2016
1	tocilizumab (atlizumab)FDA Link 06/2016
1	Cladribine FDA LinkGeneric 09/2015
1	Mitoxantrone (Novantrone)FDA LinkGeneric 09/2015
1	Imipenem Drug Combination Cilastatin (Primaxin)FDA Link 01/2015
1	Cefepime (Maxipime)FDA LinkGeneric 01/2015
1	Meropenem (Merrem)FDA LinkGeneric 01/2015
1	CefozopranIBA 01/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013
1	Valacyclovir (Valtrex)FDA LinkGeneric 12/2012
1	Nuclear Proteins (Protein, Nuclear)IBA 10/2012
1	Tetracycline (Achromycin)FDA LinkGeneric 10/2012
1	Imatinib Mesylate (Gleevec)FDA Link 09/2012
1	Concanavalin AIBA 05/2012
1	phosphatidylcholine-ceramide phosphocholine transferaseIBA 05/2012
1	AnthracyclinesIBA 04/2012
1	AclarubicinIBA 04/2012
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 04/2012

Therapy/Procedure

17	Therapeutics 04/2024 - 02/2002
10	Drug Therapy (Chemotherapy) 01/2013 - 02/2002
3	Remission Induction 04/2012 - 02/2002
2	Oral Administration 08/2009 - 02/2005
1	Stem Cell Transplantation 10/2013